Intersect ENT has agreed to acquire Fiagon AG Medical Technologies – Click here to learn more

Investor Relations

News

Date Title and Summary Additional Formats
Toggle Summary Sinexus Welcomes New CEO and Completes Series B
Toggle Summary Sinexus changes name to Intersect ENT, Initiates Pivotal Study
Toggle Summary Intersect ENT Closes Series C Financing, Recognized for Clinical Science
Toggle Summary Intersect ENT Announces U.S. Food and Drug Administration Approval for First Drug Releasing Implant for Chronic Sinusitis Patients
Toggle Summary Intersect ENT Announces Positive Data from Pivotal Study of Propel Implant, Showing Significantly Improved Outcomes For Sinus Surgery
Toggle Summary Intersect ENT Quadruples Operation Size with Expansion to New Facility in Menlo Park, Calif.
Toggle Summary Groundbreaking Clinical Evidence Demonstrates Benefit of PROPEL Implant for Chronic Sinusitis Patients
Toggle Summary Intersect ENT Announces FDA Approval of New Steroid-Releasing Implant, Allowing More Chronic Sinusitis Patients to Benefit from Localized Drug Delivery
Toggle Summary Intersect ENT Initiates U.S. Clinical Study of a Novel In-Office Treatment for Chronic Sinusitis Patients
Toggle Summary Intersect ENT Raises $30 Million Funds to Fuel Commercial Expansion and Development of Next Generation Products for Chronic Sinusitis Sufferers